Structure Therapeutics Inc. (GPCR)
GPCR Stock Price Chart
Explore Structure Therapeutics Inc. interactive price chart. Choose custom timeframes to analyze GPCR price movements and trends.
GPCR Company Profile
Discover essential business fundamentals and corporate details for Structure Therapeutics Inc. (GPCR) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
3 Feb 2023
Employees
163.00
Website
https://structuretx.comCEO
Raymond C. Stevens
Description
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.
GPCR Financial Timeline
Browse a chronological timeline of Structure Therapeutics Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 25 Feb 2026
Upcoming earnings on 12 Nov 2025
EPS estimate is -$0.38.
Earnings released on 6 Aug 2025
EPS came in at -$0.36 falling short of the estimated -$0.28 by -28.57%.
Earnings released on 8 May 2025
EPS came in at -$0.27 falling short of the estimated -$0.24 by -12.50%.
Earnings released on 27 Feb 2025
EPS came in at -$0.22 surpassing the estimated -$0.23 by +4.35%, while revenue for the quarter reached $1.78M .
Earnings released on 13 Nov 2024
EPS came in at -$0.20 falling short of the estimated -$0.19 by -5.26%.
Earnings released on 8 Aug 2024
EPS came in at -$0.18 surpassing the estimated -$0.23 by +21.74%.
Earnings released on 9 May 2024
EPS came in at -$0.19 surpassing the estimated -$0.21 by +9.52%.
Earnings released on 8 Mar 2024
EPS came in at -$0.17 surpassing the estimated -$0.21 by +19.05%, while revenue for the quarter reached $1.33M .
Earnings released on 14 Nov 2023
EPS came in at -$0.62 falling short of the estimated -$0.29 by -113.79%.
Earnings released on 10 Aug 2023
EPS came in at -$0.60 falling short of the estimated -$0.28 by -114.29%.
Earnings released on 11 May 2023
EPS came in at -$0.25 surpassing the estimated -$0.41 by +39.02%.
Earnings released on 31 Mar 2023
EPS came in at -$1.14 falling short of the estimated -$0.82 by -39.02%.
Earnings released on 30 Sept 2022
EPS came in at -$0.12 .
Earnings released on 30 Jun 2022
EPS came in at -$0.13 .
Earnings released on 31 Mar 2022
EPS came in at -$0.12 .
Earnings released on 31 Dec 2021
EPS came in at -$0.00 .
GPCR Stock Performance
Access detailed GPCR performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.